Marcum MicroCap Conference

Thursday, May 30, 2013
Grand Hyatt
109 E 42nd Street
New York, NY 10017

DelMar PHARMACEUTICALS

Breakthrough Cancer Therapeutics

OTCQB: DMPI

JEFFREY BACHA, PRESIDENT & CEO

MAY 30, 2013

MARCUM ACCOUNTANTS • ADVISORS

Safe Harbor

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein or made in the course of the presentation are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

Our Mission

To benefit patients and create shareholder value by rapidly developing and commercializing well-validated anti-cancer therapies in high-impact orphan cancer indications where patients have failed modern therapy.

Value Proposition

- *Clinical and Commercial-stage pharmaceutical company*
- *Well-validated lead drug candidate*
- *Hold commercial rights to lead product in China*
- *Management has a history of successful exits*
- *Clinical team successfully developed Synribo®*
- *Streamlined clinical and global commercialization plan*
- *Strong financial position*
- *Public listing (OTCQB: DMPI)*

VAL-083

Small molecule cancer therapy for refractory glioblastoma multiforme

VAL-083: *DelMar's First Product Opportunity*



- **Currently undergoing Phase I/II clinical trial in patients with refractory glioblastoma multiforme (GBM)**
- **Small-molecule chemotherapeutic**
- **Studied in previous human clinical studies at the National Cancer Institute (USA)**
- **Favorable safety profile**
- **Well characterized mechanism of action**
- **Approved in China: Leukemia & Lung Cancer**

VAL-083: Product Development Strategy



Glioblastoma Multiforme

Current Treatment Paradigm



Glioblastoma Multiforme

The Problem

- Glioblastoma Multiforme (GBM): The most common and aggressive form of brain cancer
- Affects approx. 15,000 adults each year in USA
- Prognosis is very poor
  - Without Treatment = 4 ½ months
  - With Optimal Treatment = 15 months
- Resistance to standard chemotherapy is high
- Approximately half of patients tumors fail all other treatments
  - We know why!!!

Glioblastoma Multiforme

The Problem: MGMT Drug Resistance

- MGMT is a natural enzyme that causes resistance to Temodar™
- *Highly correlated with patient response & survival*
- *Modern approaches such as vaccines & immunotherapies will not address this problem*



Source: Hegi ME et al. N Engl J Med. 2005; 352(10):997-1003.

Glioblastoma Multiforme (GBM)

Potential Solution: VAL-083

- Novel small molecule drug candidate
- Data from National Cancer Institute demonstrates activity in GBM
- Works differently than other chemotherapies
- Not subject to MGMT resistance mechanism

U251 cell line
Adult GBM

MGMT negative
TMZ sensitive



T98G
Adult GBM

MGMT positive
TMZ resistant



Glioblastoma Multiforme (GBM)

VAL-083 Clinical Trial

- Phase I/II Study being conducted in USA
- Patients have failed Temodar® and Avastin®
- Goals of the Trial
  - Modernize Dosing Regimen
  - Confirm safety provile
  - Demonstrate ability to shrink or halt growth of tumors
- Initial Phase: Dose Modernization (20-30 patients)
- Leads to 80-100 patient registration trial
  - Open label design

VAL-083

Evidence of Clinical Efficacy in GBM

VAL-083 historical clinical data demonstrates comparable incremental survival benefit and overall survival comparable to today's standard of care

Treatment of GBM	**temozolomide** *(Phase III Stupp 2005)*	**VAL-083** *(Phase II Eagan 1979)*
Median Overall Survival *RT + Chemo*	58 weeks	67 weeks
OS Benefit of adding Chemo: *RT & Chemo vs. XRT Only*	2.5 months (p<0.01)	8.4 months (p=0.02)
Sample (n=)	573	42
Randomization	1:1	1:1





Toxicity Comparison

	Temodar	BCNU	VAL-083
Severe toxicity reported (>2%)	Hematologic*, nausea, vomiting, fatigue, asthenia, neuropathy	Hematologic*, pulmonary, nausea, vomiting, encephalopathy, renal	Hematologic*
*DLT			
NADR	21-28 days	21-35 days	18-21 days
Recovery	Within 14 days	42-56 days	Within 7-8 days

As reported by BC Cancer Agency monograph (2010)

literature (1970s) & China commercial experience

Illustrative Comparison of Dosing Regimen

"Hit the tumor harder; more often"

DelMar Pharma "modernized" dosing regimen

NCI regimen from published efficacy studies



VAL-083 Dose-Escalation Study Illustration



VAL-083 Phase I/II Clinical Trial Results to Date (AACR 2013)

- VAL-083 is safe and well tolerated at doses tested to date
- A portion (33%) of patients tumors were observed to shrink or stop growing following initiation of treatment
- Doses to date are lower than NCI-regimen
- Plasma exposure observed to increase in accordance with dose

VAL-083: Clinical Development in GBM

Interim Results Presented at AACR (study ongoing)

Patient Brainscans (MRI) impact on tumor following treatment with VAL-083

Before treatment with VAL-083



After treatment with VAL-083



Patient #2

Before treatment with VAL-083



After treatment with VAL-083



Patient #5

AACR2013
Poster Presentation

VAL-083: Clinical Development in GBM

- Current Phase I/II Study ➔ potentially position DelMar for advancement to registration trials



- ✓ **Re-confirmed published activity against GBM**
- ✓ **Well defined registration trial**
- ✓ **Registration-ready commercial scale CMC**
- ✓ **New patents claims / Orphan drug protection**

DelMar's Unique Partnership in China

Commercial and development partnership with Guangxi Wuzhou Pharmaceutical Group Co. Ltd.

- Provides DelMar with global rights to VAL-083, which is already approved as a cancer chemotherapy in China
- Near-term revenue opportunity for DelMar in high-growth international markets
- Guangxi Wuzhou Pharma will fund any clinical activities in China
- DelMar plans to partner China marketing rights to access an established sales force and generate royalty revenue



VAL-083:
China Opportunity

- Major potential market opportunity: Lung cancer = 1,000,000 new cases annually by 2025
- Challenge: Current sales in China are minimal
  - Drug is not well positioned vis-à-vis standard of care in approved indications
- Solution: New data to promote sales
  - Near Term: Reposition for refractory therapy in approved indications
  - Longer Term: Expand market with new indications
- Seeking sales & marketing partnership to generate royalty revenue

VAL-083

Intellectual Property:

Orphan Drug Protection: Provides 7 – 10 years of market exclusivity

- Granted in USA 2012
- Granted in Europe 2013

Filed Seven New Patent Applications since 2010

Leadership & Experience

Jeffrey Bacha, BSc MBA: CEO & President

- 20 years of experience in biotech and pharmaceuticals
- Founding CEO, Inimex Pharmaceuticals
- Senior Manager & Director, KPMG Health Ventures
- Emory Univ., School of Business
- UC San Diego, BioPhysics/PreMed

Dennis Brown, PhD: Chief Scientific Officer

- Founder: Matix Pharmaceuticals (acquired by Chiron)
- Founder: Chemgenex (acquired by Cephalon)
- 30 years cancer drug discovery and development
- Harvard Medical School, Assistant Professor
- Stanford Univ. Med School, Research Associate
- NYU, PhD Radiation and Cancer Biology

DelMar PHARMACEUTICALS
Development Team

Responsible for successful development & commercialization of more than 20 oncology products.

Directors & Advisors

Bill Garner, MD,	Director, coFounder DelMar; CEO Invion Ltd. (ASX:IVX)
John K. Bell, CA	Director, President of Onbelay Capital
Victor Levin, MD	Prof. Emeritus MD Anderson Cancer Center (Neuro-Oncology)
Susan Chang, MD	Chair, NeuroOncology Department UCSF
James Perry, MD	Chair, Canadian Brain Tumor Consortium
Howard Burris, MD	Director, Sarah Cannon Cancer Research Institute
Bill Bodell, PhD	Prof. Emeritus UC Berkley (DNA Damage & Repair)
Dan Zhang, MD	SFDA Oncology Advisory Panel (China FDA)
Christine Charette	Former Biotech Analyst, BMO Nesbitt Burns
Sol Barer, PhD	Founder, Celgene

Track Record of Achievements

- Launched clinical trial in 2011
- Awarded Orphan Drug Designation by USFDA & EMEA for VAL-083
- Demonstrated clinical activity with lead drug candidate
- Awarded three research grants from National Research Council of Canada
- Acquired exclusive commercial rights to VAL-083 in China
- Filed seven new patents in 2011/12
- Established a highly-experienced drug development team and advisors
- Named to “Ready to Rocket” list in 2010/2012/2013
- 2010 Winner: Discovery Parks Business Plan Competition
- Presented favorable interim data from clinical trials at leading cancer meetings 2012/2013

DelMar's Anticipated Clinical Data Presentations from Glioblastoma Trial

American Association of Cancer Research (AACR)	***Data Presented 10-Apr/2013***
American Society of Clinical Oncology (ASCO)	***Presentation 1-Jun/2013***
Society for NeuroOncology Annual Meeting (SNO)	**Nov 21 – 24 (San Francisco CA)**

CAPITALIZATION

Capital Raised to Date:	**$13.6 million**
Shares Outstanding:	**30.6 million**
Market Capitalization:	**$69 million**
Ticker (OTCQB):	**DMPI**
Auditor:	**PricewaterhouseCoopers LLP**

DelMar Pharma Investment Thesis

- *Clinical-stage oncology company*
- *Proven drug candidate*
- *Streamlined commercialization plan*
- *Attractive valuation*
- *Highly experienced team*
- *OTCQB: DMPI*

Thank You

DelMar Pharmaceuticals, Inc.

www.delmarpharma.com

Jeffrey Bacha, BSc, MBA – President & CEO

- jbacha@delmarpharma.com
- +1 604 317 7022

Dennis Brown, PhD – Chief Scientific Officer

- dbrown@delmarpharma.com
- +1 650 269 1984

Scott Praill, CFA – Chief Financial Officer

- spraill@delmarpharma.com
- +1 604 202 1384

Corporate Headquarters:
Suite 720 – 999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5

Clinical Operations:
3475 Edison Way, Suite R
Menlo Park, California 94025
USA